As of 2025-08-06, the EV/EBITDA ratio of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO.NS) is 35.68. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. GLAXO.NS's latest enterprise value is 472,101.60 mil INR. GLAXO.NS's TTM EBITDA according to its financial statements is 13,232.92 mil INR. Dividing these 2 quantities gives us the above GLAXO.NS EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 20.0x - 23.6x | 21.8x |
| Forward P/E multiples | 18.8x - 21.5x | 20.2x |
| Fair Price | 1,644.11 - 1,925.70 | 1,771.57 |
| Upside | -42.7% - -32.9% | -38.3% |
| Date | EV/EBITDA |
| 2025-07-31 | 39.44 |
| 2025-07-30 | 39.85 |
| 2025-07-29 | 39.09 |
| 2025-07-28 | 38.39 |
| 2025-07-25 | 39.30 |
| 2025-07-24 | 39.35 |
| 2025-07-23 | 39.03 |
| 2025-07-22 | 38.65 |
| 2025-07-21 | 38.79 |
| 2025-07-18 | 39.02 |
| 2025-07-17 | 39.53 |
| 2025-07-16 | 39.53 |
| 2025-07-15 | 39.85 |
| 2025-07-14 | 39.78 |
| 2025-07-11 | 40.43 |
| 2025-07-10 | 40.59 |
| 2025-07-09 | 41.27 |
| 2025-07-08 | 40.68 |
| 2025-07-07 | 40.87 |
| 2025-07-04 | 41.00 |
| 2025-07-03 | 41.18 |
| 2025-07-02 | 41.07 |
| 2025-07-01 | 41.94 |
| 2025-06-30 | 42.32 |
| 2025-06-27 | 43.33 |
| 2025-06-26 | 41.10 |
| 2025-06-25 | 40.75 |
| 2025-06-24 | 40.36 |
| 2025-06-23 | 39.57 |
| 2025-06-20 | 39.91 |
| 2025-06-19 | 39.65 |
| 2025-06-18 | 40.81 |
| 2025-06-17 | 40.52 |
| 2025-06-16 | 41.77 |
| 2025-06-13 | 41.01 |
| 2025-06-12 | 41.36 |
| 2025-06-11 | 42.24 |
| 2025-06-10 | 42.47 |
| 2025-06-09 | 42.55 |
| 2025-06-06 | 42.97 |
| 2025-06-05 | 43.15 |
| 2025-06-04 | 42.92 |
| 2025-06-03 | 40.48 |
| 2025-06-02 | 40.73 |
| 2025-05-30 | 41.17 |
| 2025-05-29 | 40.81 |
| 2025-05-28 | 41.64 |
| 2025-05-27 | 38.68 |
| 2025-05-26 | 36.74 |
| 2025-05-23 | 37.56 |